Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 2/20 | 0.47 |
| ▸ | HTR7 | P34969 | 4/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL854696 | 0.94 | PIK3CD (0.48) | PIK3CDCYP1A2TDP1KDM1AHTR7 | |
| SCHEMBL27370143 | 0.92 | HTR7 (0.49) | PIK3CDCYP1A2TDP1KDM1AHTR7 | |
| SCHEMBL27370138 | 0.92 | HTR7 (0.49) | PIK3CDCYP1A2TDP1KDM1AHTR7 | |
| SCHEMBL27370871 | 0.92 | HTR7 (0.49) | PIK3CDCYP1A2TDP1KDM1AHTR7 | |
| SCHEMBL488861 | 0.88 | ALOX15 (0.56) | PIK3CDCYP1A2TDP1KDM1AHTR7 | |
| SCHEMBL8265175 | 0.84 | CYP1A2 (0.50) | PIK3CDCYP1A2TDP1KDM1AHTR7 | |
| SCHEMBL13925521 | 0.84 | CYP1A2 (0.50) | PIK3CDCYP1A2TDP1KDM1AHTR7 | |
| SCHEMBL23823660 | 0.83 | CYP1A2 (0.64) | PIK3CDCYP1A2TDP1KDM1AHTR7 | |
| SCHEMBL3319469 | 0.82 | PIK3CD (0.48) | PIK3CDCYP1A2TDP1KDM1AHTR7 | |
| SCHEMBL6644497 | 0.82 | SIGMAR1 (0.49) | KEAP1SMN1; SMN2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3796900-B1 | TRITERPENE AMINE DERIVATIVES | DFH THERAPEUTICS (US) | 2026-04-08 | — | — | EP | disclosed |
| US-11236122-B2 | Triterpene amine derivatives | DFH THERAPEUTICS (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210253627-A1 | TRITERPENE AMINE DERIVATIVES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-08-19 | — | — | US | disclosed |
| EP-2063887-B1 | NEW SMALL MOLECULE INHIBITORS OF MDM2 AND THE USES THEREOF | UNIV MICHIGAN (US) | 2013-05-29 | — | — | EP | disclosed |
| US-8354407-B2 | 2-anilino-4-(heterocyclic)amino-pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-15 | — | — | US | disclosed |
| US-8354407-B2 | 2-anilino-4-(heterocyclic)amino-pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-15 | — | — | US | disclosed |
| US-8354407-B2 | 2-anilino-4-(heterocyclic)amino-pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-15 | — | — | US | disclosed |
| US-20090227586-A1 | 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227586-A1 | 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227586-A1 | 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-10 | — | — | US | disclosed |
| EP-2054392-A2 | 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES AS INHIBITORS OF PROTEIN KINASE C-ALPHA | Boehringer Ingelheim International GmbH (DE) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008036168-A2 | NEW SMALL MOLECULE INHIBITORS OF MDM2 AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007146981-A2 | 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES AS INHIBITORS OF PROTEIN KINASE C-ALPHA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007146981-A2 | 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES AS INHIBITORS OF PROTEIN KINASE C-ALPHA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-21 | — | — | WO | disclosed |
| US-20070293494-A1 | 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines | DJUNG JANE F | 2007-12-20 | — | — | US | disclosed |
| US-20070293494-A1 | 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines | DJUNG JANE F | 2007-12-20 | — | — | US | disclosed |
| US-20070293494-A1 | 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines | DJUNG JANE F | 2007-12-20 | — | — | US | disclosed |
| US-5561139-A | IMMUNOSUPPRESSANTS; SIDE EFFECT REDUCTION | ABBOTT LABORATORIES (US) | 1996-10-01 | — | — | US | disclosed |
| US-5530120-A | ANALOGS OF ASCOMYCIN AND FK-506 AS IMMUNOSUPPRESSANTS AND-MODULATORS; SIDE EFFECT REDUCTION | ABBOTT LABORATORIES (US) | 1996-06-25 | — | — | US | disclosed |
| WO-1994021634-A1 | SUBSTITUTED ALICYCLIC-ALIPHATIC AMINE-CONTAINING MACROCYCLIC IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253627-A1 | TRITERPENE AMINE DERIVATIVES | BET1, PGGT1B, NFATC1 | PIK3CD 1146/4885CYP1A2 962/4885TDP1 1420/4885 |
| US-20070293494-A1 | 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines | PRKCA, PRKCG, PRKCH | PIK3CD 102/4885CYP1A2 3383/4885TDP1 1494/4885 |
| US-20090227586-A1 | 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES | PRKCA, PRKCG, PRKCH | PIK3CD 102/4885CYP1A2 3383/4885TDP1 1494/4885 |
| US-11236122-B2 | Triterpene amine derivatives | BET1, PGGT1B, NFATC1 | PIK3CD 1146/4885CYP1A2 962/4885TDP1 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.